Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

Pseudogene Associated Recurrent Gene Fusion in Prostate Cancer.

Chakravarthi BV, Dedigama-Arachchige P, Carskadon S, Sundaram SK, Li J, Wu KH, Chandrashekar DS, Peabody JO, Stricker H, Hwang C, Chitale DA, Williamson SR, Gupta NS, Navone NM, Rogers C, Menon M, Varambally S, Palanisamy N.

Neoplasia. 2019 Aug 22;21(10):989-1002. doi: 10.1016/j.neo.2019.07.010. [Epub ahead of print]

2.

Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease.

Liu H, He J, Koh SP, Zhong Y, Liu Z, Wang Z, Zhang Y, Li Z, Tam BT, Lin P, Xiao M, Young KH, Amini B, Starbuck MW, Lee HC, Navone NM, Davis RE, Tong Q, Bergsagel PL, Hou J, Yi Q, Orlowski RZ, Gagel RF, Yang J.

Sci Transl Med. 2019 May 29;11(494). pii: eaau9087. doi: 10.1126/scitranslmed.aau9087.

PMID:
31142679
3.

Genome-wide CRISPR screens reveal synthetic lethality of RNASEH2 deficiency and ATR inhibition.

Wang C, Wang G, Feng X, Shepherd P, Zhang J, Tang M, Chen Z, Srivastava M, McLaughlin ME, Navone NM, Hart GT, Chen J.

Oncogene. 2019 Apr;38(14):2451-2463. doi: 10.1038/s41388-018-0606-4. Epub 2018 Dec 7.

4.

Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models.

Navone NM, van Weerden WM, Vessella RL, Williams ED, Wang Y, Isaacs JT, Nguyen HM, Culig Z, van der Pluijm G, Rentsch CA, Marques RB, de Ridder CMA, Bubendorf L, Thalmann GN, Brennen WN, Santer FR, Moser PL, Shepherd P, Efstathiou E, Xue H, Lin D, Buijs J, Bosse T, Collins A, Maitland N, Buzza M, Kouspou M, Achtman A, Taylor RA, Risbridger G, Corey E.

Prostate. 2018 Dec;78(16):1262-1282. doi: 10.1002/pros.23701. Epub 2018 Aug 2.

PMID:
30073676
5.

FGF-2 is a driving force for chromosomal instability and a stromal factor associated with adverse clinico-pathological features in prostate cancer.

Pecqueux C, Arslan A, Heller M, Falkenstein M, Kaczorowski A, Tolstov Y, Sültmann H, Grüllich C, Herpel E, Duensing A, Kristiansen G, Hohenfellner M, Navone NM, Duensing S.

Urol Oncol. 2018 Aug;36(8):365.e15-365.e26. doi: 10.1016/j.urolonc.2018.05.020. Epub 2018 Jun 7.

PMID:
29887238
6.

An In Vivo Screen Identifies PYGO2 as a Driver for Metastatic Prostate Cancer.

Lu X, Pan X, Wu CJ, Zhao D, Feng S, Zang Y, Lee R, Khadka S, Amin SB, Jin EJ, Shang X, Deng P, Luo Y, Morgenlander WR, Weinrich J, Lu X, Jiang S, Chang Q, Navone NM, Troncoso P, DePinho RA, Wang YA.

Cancer Res. 2018 Jul 15;78(14):3823-3833. doi: 10.1158/0008-5472.CAN-17-3564. Epub 2018 May 16.

7.

Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer.

Zhao D, Lu X, Wang G, Lan Z, Liao W, Li J, Liang X, Chen JR, Shah S, Shang X, Tang M, Deng P, Dey P, Chakravarti D, Chen P, Spring DJ, Navone NM, Troncoso P, Zhang J, Wang YA, DePinho RA.

Nature. 2017 Feb 23;542(7642):484-488. doi: 10.1038/nature21357. Epub 2017 Feb 6.

8.

Targeted molecular-genetic imaging and ligand-directed therapy in aggressive variant prostate cancer.

Ferrara F, Staquicini DI, Driessen WHP, D'Angelo S, Dobroff AS, Barry M, Lomo LC, Staquicini FI, Cardó-Vila M, Soghomonyan S, Alauddin MM, Flores LG 2nd, Arap MA, Lauer RC, Mathew P, Efstathiou E, Aparicio AM, Troncoso P, Navone NM, Logothetis CJ, Marchiò S, Gelovani JG, Sidman RL, Pasqualini R, Arap W.

Proc Natl Acad Sci U S A. 2016 Nov 8;113(45):12786-12791. doi: 10.1073/pnas.1615400113. Epub 2016 Oct 24.

9.

Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomas.

Kleb B, Estécio MR, Zhang J, Tzelepi V, Chung W, Jelinek J, Navone NM, Tahir S, Marquez VE, Issa JP, Maity S, Aparicio A.

Epigenetics. 2016 Mar 3;11(3):184-93. doi: 10.1080/15592294.2016.1146851. Epub 2016 Feb 18.

10.

Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer.

Qiao Y, Feng FY, Wang Y, Cao X, Han S, Wilder-Romans K, Navone NM, Logothetis C, Taichman RS, Keller ET, Palapattu GS, Alva AS, Smith DC, Tomlins SA, Chinnaiyan AM, Morgan TM.

Neoplasia. 2016 Jan;18(1):1-9. doi: 10.1016/j.neo.2015.11.009.

11.

BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer.

Asangani IA, Wilder-Romans K, Dommeti VL, Krishnamurthy PM, Apel IJ, Escara-Wilke J, Plymate SR, Navone NM, Wang S, Feng FY, Chinnaiyan AM.

Mol Cancer Res. 2016 Apr;14(4):324-31. doi: 10.1158/1541-7786.MCR-15-0472. Epub 2016 Jan 20.

12.

A 3D in vitro model of patient-derived prostate cancer xenograft for controlled interrogation of in vivo tumor-stromal interactions.

Fong EL, Wan X, Yang J, Morgado M, Mikos AG, Harrington DA, Navone NM, Farach-Carson MC.

Biomaterials. 2016 Jan;77:164-72. doi: 10.1016/j.biomaterials.2015.10.059. Epub 2015 Nov 9.

13.

Mature adipocytes in bone marrow protect myeloma cells against chemotherapy through autophagy activation.

Liu Z, Xu J, He J, Liu H, Lin P, Wan X, Navone NM, Tong Q, Kwak LW, Orlowski RZ, Yang J.

Oncotarget. 2015 Oct 27;6(33):34329-41. doi: 10.18632/oncotarget.6020.

14.

PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3.

Salameh A, Lee AK, Cardó-Vila M, Nunes DN, Efstathiou E, Staquicini FI, Dobroff AS, Marchiò S, Navone NM, Hosoya H, Lauer RC, Wen S, Salmeron CC, Hoang A, Newsham I, Lima LA, Carraro DM, Oliviero S, Kolonin MG, Sidman RL, Do KA, Troncoso P, Logothetis CJ, Brentani RR, Calin GA, Cavenee WK, Dias-Neto E, Pasqualini R, Arap W.

Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):8403-8. doi: 10.1073/pnas.1507882112. Epub 2015 Jun 15.

15.

Targeting the interleukin-11 receptor α in metastatic prostate cancer: A first-in-man study.

Pasqualini R, Millikan RE, Christianson DR, Cardó-Vila M, Driessen WH, Giordano RJ, Hajitou A, Hoang AG, Wen S, Barnhart KF, Baze WB, Marcott VD, Hawke DH, Do KA, Navone NM, Efstathiou E, Troncoso P, Lobb RR, Logothetis CJ, Arap W.

Cancer. 2015 Jul 15;121(14):2411-21. doi: 10.1002/cncr.29344. Epub 2015 Apr 1.

16.

Selection and identification of ligand peptides targeting a model of castrate-resistant osteogenic prostate cancer and their receptors.

Mandelin J, Cardó-Vila M, Driessen WH, Mathew P, Navone NM, Lin SH, Logothetis CJ, Rietz AC, Dobroff AS, Proneth B, Sidman RL, Pasqualini R, Arap W.

Proc Natl Acad Sci U S A. 2015 Mar 24;112(12):3776-81. doi: 10.1073/pnas.1500128112. Epub 2015 Mar 11.

17.

Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases.

Wan X, Corn PG, Yang J, Palanisamy N, Starbuck MW, Efstathiou E, Li Ning Tapia EM, Zurita AJ, Aparicio A, Ravoori MK, Vazquez ES, Robinson DR, Wu YM, Cao X, Iyer MK, McKeehan W, Kundra V, Wang F, Troncoso P, Chinnaiyan AM, Logothetis CJ, Navone NM.

Sci Transl Med. 2014 Sep 3;6(252):252ra122. doi: 10.1126/scitranslmed.3009332. Erratum in: Sci Transl Med. 2015 May 13;7(287):287er3. Tapia, Elsa M Li-Ning [corrected to Li Ning Tapia, Elsa M].

18.

Hydrogel-based 3D model of patient-derived prostate xenograft tumors suitable for drug screening.

Fong EL, Martinez M, Yang J, Mikos AG, Navone NM, Harrington DA, Farach-Carson MC.

Mol Pharm. 2014 Jul 7;11(7):2040-50. doi: 10.1021/mp500085p. Epub 2014 Apr 29.

19.

Arachidonic acid metabolism in human prostate cancer.

Yang P, Cartwright CA, Li J, Wen S, Prokhorova IN, Shureiqi I, Troncoso P, Navone NM, Newman RA, Kim J.

Int J Oncol. 2012 Oct;41(4):1495-503. doi: 10.3892/ijo.2012.1588. Epub 2012 Aug 10.

20.

Hedgehog signaling inhibition by the small molecule smoothened inhibitor GDC-0449 in the bone forming prostate cancer xenograft MDA PCa 118b.

Karlou M, Lu JF, Wu G, Maity S, Tzelepi V, Navone NM, Hoang A, Logothetis CJ, Efstathiou E.

Prostate. 2012 Nov;72(15):1638-47. doi: 10.1002/pros.22517. Epub 2012 Mar 27.

21.

Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma.

Yang J, He J, Wang J, Cao Y, Ling J, Qian J, Lu Y, Li H, Zheng Y, Lan Y, Hong S, Matthews J, Starbuck MW, Navone NM, Orlowski RZ, Lin P, Kwak LW, Yi Q.

Leukemia. 2012 Sep;26(9):2114-23. doi: 10.1038/leu.2012.71. Epub 2012 Mar 19. Erratum in: Leukemia. 2015 Feb;29(2):515.

22.

Activation of β-catenin signaling in androgen receptor-negative prostate cancer cells.

Wan X, Liu J, Lu JF, Tzelepi V, Yang J, Starbuck MW, Diao L, Wang J, Efstathiou E, Vazquez ES, Troncoso P, Maity SN, Navone NM.

Clin Cancer Res. 2012 Feb 1;18(3):726-36. doi: 10.1158/1078-0432.CCR-11-2521.

23.

Androgen regulation of 5α-reductase isoenzymes in prostate cancer: implications for prostate cancer prevention.

Li J, Ding Z, Wang Z, Lu JF, Maity SN, Navone NM, Logothetis CJ, Mills GB, Kim J.

PLoS One. 2011;6(12):e28840. doi: 10.1371/journal.pone.0028840. Epub 2011 Dec 14.

24.

Effect of transforming growth factor beta (TGF-β) receptor I kinase inhibitor on prostate cancer bone growth.

Wan X, Li ZG, Yingling JM, Yang J, Starbuck MW, Ravoori MK, Kundra V, Vazquez E, Navone NM.

Bone. 2012 Mar;50(3):695-703. doi: 10.1016/j.bone.2011.11.022. Epub 2011 Dec 7.

25.

Modeling a lethal prostate cancer variant with small-cell carcinoma features.

Tzelepi V, Zhang J, Lu JF, Kleb B, Wu G, Wan X, Hoang A, Efstathiou E, Sircar K, Navone NM, Troncoso P, Liang S, Logothetis CJ, Maity SN, Aparicio AM.

Clin Cancer Res. 2012 Feb 1;18(3):666-77. doi: 10.1158/1078-0432.CCR-11-1867. Epub 2011 Dec 12.

26.

Vascular patterning and permeability in prostate cancer models with differing osteogenic properties.

Dafni H, Burghardt AJ, Majumdar S, Navone NM, Ronen SM.

NMR Biomed. 2012 Jun;25(6):843-51. doi: 10.1002/nbm.1800. Epub 2011 Dec 2.

PMID:
22134886
27.

Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer.

Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA, Patel S, Wang X, Liang H, Yu J, Palanisamy N, Siddiqui J, Yan W, Cao X, Mehra R, Sabolch A, Basrur V, Lonigro RJ, Yang J, Tomlins SA, Maher CA, Elenitoba-Johnson KS, Hussain M, Navone NM, Pienta KJ, Varambally S, Feng FY, Chinnaiyan AM.

Cancer Cell. 2011 May 17;19(5):664-78. doi: 10.1016/j.ccr.2011.04.010. Erratum in: Cancer Cell. 2013 Apr 15;23(4):557.

28.

Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient's tumor: morphological, immunohistochemical, and gene expression profiles.

Aparicio A, Tzelepi V, Araujo JC, Guo CC, Liang S, Troncoso P, Logothetis CJ, Navone NM, Maity SN.

Prostate. 2011 Jun 1;71(8):846-56. doi: 10.1002/pros.21301. Epub 2010 Nov 17.

29.

Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature.

Mohamedali KA, Li ZG, Starbuck MW, Wan X, Yang J, Kim S, Zhang W, Rosenblum MG, Navone NM.

Clin Cancer Res. 2011 Apr 15;17(8):2328-38. doi: 10.1158/1078-0432.CCR-10-2943. Epub 2011 Feb 22.

30.

Prioritizing genes associated with prostate cancer development.

Gorlov IP, Sircar K, Zhao H, Maity SN, Navone NM, Gorlova OY, Troncoso P, Pettaway CA, Byun JY, Logothetis CJ.

BMC Cancer. 2010 Nov 2;10:599. doi: 10.1186/1471-2407-10-599.

31.

TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate.

Guo CC, Dancer JY, Wang Y, Aparicio A, Navone NM, Troncoso P, Czerniak BA.

Hum Pathol. 2011 Jan;42(1):11-7. doi: 10.1016/j.humpath.2010.05.026. Epub 2010 Oct 30.

32.

P-TEFb joins the family of cdks in oncology, promotes cell growth of cancer cells.

Navone NM.

Cell Cycle. 2010 Aug 1;9(15):2935. doi: 10.4161/cc.9.15.12738. Epub 2010 Aug 1. No abstract available.

PMID:
20703082
33.

Adipose tissue-derived stem cells promote prostate tumor growth.

Prantl L, Muehlberg F, Navone NM, Song YH, Vykoukal J, Logothetis CJ, Alt EU.

Prostate. 2010 Nov 1;70(15):1709-15. doi: 10.1002/pros.21206.

34.

Quantification of mineralized bone response to prostate cancer by noninvasive in vivo microCT and non-destructive ex vivo microCT and DXA in a mouse model.

Ravoori M, Czaplinska AJ, Sikes C, Han L, Johnson EM, Qiao W, Ng C, Cody DD, Murphy WA, Do KA, Navone NM, Kundra V.

PLoS One. 2010 Mar 29;5(3):e9854. doi: 10.1371/journal.pone.0009854.

35.

Androgen depletion up-regulates cadherin-11 expression in prostate cancer.

Lee YC, Cheng CJ, Huang M, Bilen MA, Ye X, Navone NM, Chu K, Kao HH, Yu-Lee LY, Wang Z, Lin SH.

J Pathol. 2010 May;221(1):68-76. doi: 10.1002/path.2687.

36.

Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms.

Li ZG, Mathew P, Yang J, Starbuck MW, Zurita AJ, Liu J, Sikes C, Multani AS, Efstathiou E, Lopez A, Wang J, Fanning TV, Prieto VG, Kundra V, Vazquez ES, Troncoso P, Raymond AK, Logothetis CJ, Lin SH, Maity S, Navone NM.

J Clin Invest. 2008 Aug;118(8):2697-710. doi: 10.1172/JCI33093.

37.

Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer.

Lin SH, Lee YC, Choueiri MB, Wen S, Mathew P, Ye X, Do KA, Navone NM, Kim J, Tu SM, Yu-Lee LY, Logothetis CJ.

Clin Cancer Res. 2008 Jun 15;14(12):3729-36. doi: 10.1158/1078-0432.CCR-08-0472.

38.

A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation.

Lin SH, Cheng CJ, Lee YC, Ye X, Tsai WW, Kim J, Pasqualini R, Arap W, Navone NM, Tu SM, Hu M, Yu-Lee LY, Logothetis CJ.

Oncogene. 2008 Sep 4;27(39):5195-203. doi: 10.1038/onc.2008.156. Epub 2008 May 19.

39.

Understanding the biology of bone metastases: key to the effective treatment of prostate cancer.

Logothetis CJ, Navone NM, Lin SH.

Clin Cancer Res. 2008 Mar 15;14(6):1599-602. doi: 10.1158/1078-0432.CCR-07-4603. Review.

40.

The current state of preclinical prostate cancer animal models.

Pienta KJ, Abate-Shen C, Agus DB, Attar RM, Chung LW, Greenberg NM, Hahn WC, Isaacs JT, Navone NM, Peehl DM, Simons JW, Solit DB, Soule HR, VanDyke TA, Weber MJ, Wu L, Vessella RL.

Prostate. 2008 May 1;68(6):629-39. doi: 10.1002/pros.20726.

41.

Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone.

Li ZG, Yang J, Vazquez ES, Rose D, Vakar-Lopez F, Mathew P, Lopez A, Logothetis CJ, Lin SH, Navone NM.

Oncogene. 2008 Jan 24;27(5):596-603. Epub 2007 Aug 13.

PMID:
17700537
42.

A secreted isoform of ErbB3 promotes osteonectin expression in bone and enhances the invasiveness of prostate cancer cells.

Chen N, Ye XC, Chu K, Navone NM, Sage EH, Yu-Lee LY, Logothetis CJ, Lin SH.

Cancer Res. 2007 Jul 15;67(14):6544-8.

43.

Bone microenvironment and androgen status modulate subcellular localization of ErbB3 in prostate cancer cells.

Cheng CJ, Ye XC, Vakar-Lopez F, Kim J, Tu SM, Chen DT, Navone NM, Yu-Lee LY, Lin SH, Hu MC.

Mol Cancer Res. 2007 Jul;5(7):675-84.

44.

Inhibition of prostate tumor growth and bone remodeling by the vascular targeting agent VEGF121/rGel.

Mohamedali KA, Poblenz AT, Sikes CR, Navone NM, Thorpe PE, Darnay BG, Rosenblum MG.

Cancer Res. 2006 Nov 15;66(22):10919-28.

45.

In vivo imaging of prostate cancer involving bone in a mouse model.

Kundra V, Ng CS, Ma J, Bankson JA, Price RE, Cody DD, Do KA, Han L, Navone NM.

Prostate. 2007 Jan 1;67(1):50-60.

PMID:
17031813
46.

Inhibition of prostate cancer-meditated osteoblastic bone lesions by the low-calcemic analog 1alpha-hydroxymethyl-16-ene-26,27-bishomo-25-hydroxy vitamin D3.

Peleg S, Khan F, Navone NM, Cody DD, Johnson EM, Van Pelt CS, Posner GH.

J Steroid Biochem Mol Biol. 2005 Oct;97(1-2):203-11. Epub 2005 Aug 2.

PMID:
16081281
47.

[Preclinical models of prostate cancer].

Fizazi K, Navone NM.

Bull Cancer. 2005 Feb;92(2):129-41. Review. French.

48.

High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer.

Fizazi K, Sikes CR, Kim J, Yang J, Martinez LA, Olive MC, Logothetis CJ, Navone NM.

Anticancer Res. 2004 Sep-Oct;24(5A):2897-903.

49.

Isolation and culture of prostate cancer cell lines.

Navone NM, Olive M, Troncoso P.

Methods Mol Med. 2004;88:121-32. No abstract available.

PMID:
14634223
50.

Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts.

Fizazi K, Yang J, Peleg S, Sikes CR, Kreimann EL, Daliani D, Olive M, Raymond KA, Janus TJ, Logothetis CJ, Karsenty G, Navone NM.

Clin Cancer Res. 2003 Jul;9(7):2587-97.

Supplemental Content

Loading ...
Support Center